Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan
Background/Objectives: Previous studies showed that zolpidem use could be associated with increased cancer risk, but the role of zolpidem on hepatocellular carcinoma (HCC) risk remains undetermined. The study purpose was to examine the association between HCC risk and zolpidem use in Taiwan.Methods:...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00767/full |
| _version_ | 1818059817733849088 |
|---|---|
| author | Shih-Wei Lai Shih-Wei Lai Cheng-Li Lin Cheng-Li Lin Kuan-Fu Liao Kuan-Fu Liao |
| author_facet | Shih-Wei Lai Shih-Wei Lai Cheng-Li Lin Cheng-Li Lin Kuan-Fu Liao Kuan-Fu Liao |
| author_sort | Shih-Wei Lai |
| collection | DOAJ |
| description | Background/Objectives: Previous studies showed that zolpidem use could be associated with increased cancer risk, but the role of zolpidem on hepatocellular carcinoma (HCC) risk remains undetermined. The study purpose was to examine the association between HCC risk and zolpidem use in Taiwan.Methods: Using the database from the Taiwan National Health Insurance Program, we designed a case-control study which consisted of 77986 subjects aged 20 years or older with newly diagnosed HCC as the case group, and 77986 subjects without HCC as the control group, from 2000 to 2011. Ever use of zolpidem was defined as a subject who had at least a prescription for zolpidem before the index date. Never use was defined as a subject who did not have a prescription for zolpidem before the index date. The association between HCC risk and zolpidem use was determined by the odds ratio (OR) and 95% confidence interval (CI) in a multivariable logistic regression model.Results: After adjustment for confounding factors, the adjusted OR of HCC was 1.05 (95% CI 0.97, 1.13) for subjects with ever use of zolpidem, compared with never use of zolpidem. The adjusted OR of HCC was 1.01 for subjects with increasing cumulative duration of zolpidem use for every 1 year (95% CI 0.99, 1.03), compared with never use of zolpidem.Conclusion: There is no significant association between HCC risk and zolpidem use. There is no duration-dependent effect of zolpidem use on HCC risk. |
| first_indexed | 2024-12-10T13:22:33Z |
| format | Article |
| id | doaj.art-0846a56bfa8948e9b8846e024e2d8b3f |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-10T13:22:33Z |
| publishDate | 2017-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-0846a56bfa8948e9b8846e024e2d8b3f2022-12-22T01:47:17ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122017-10-01810.3389/fphar.2017.00767304406Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in TaiwanShih-Wei Lai0Shih-Wei Lai1Cheng-Li Lin2Cheng-Li Lin3Kuan-Fu Liao4Kuan-Fu Liao5College of Medicine, China Medical University, Taichung, TaiwanDepartment of Family Medicine, China Medical University Hospital, Taichung, TaiwanCollege of Medicine, China Medical University, Taichung, TaiwanManagement Office for Health Data, China Medical University Hospital, Taichung, TaiwanCollege of Medicine, Tzu Chi University, Hualien, TaiwanDepartment of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, TaiwanBackground/Objectives: Previous studies showed that zolpidem use could be associated with increased cancer risk, but the role of zolpidem on hepatocellular carcinoma (HCC) risk remains undetermined. The study purpose was to examine the association between HCC risk and zolpidem use in Taiwan.Methods: Using the database from the Taiwan National Health Insurance Program, we designed a case-control study which consisted of 77986 subjects aged 20 years or older with newly diagnosed HCC as the case group, and 77986 subjects without HCC as the control group, from 2000 to 2011. Ever use of zolpidem was defined as a subject who had at least a prescription for zolpidem before the index date. Never use was defined as a subject who did not have a prescription for zolpidem before the index date. The association between HCC risk and zolpidem use was determined by the odds ratio (OR) and 95% confidence interval (CI) in a multivariable logistic regression model.Results: After adjustment for confounding factors, the adjusted OR of HCC was 1.05 (95% CI 0.97, 1.13) for subjects with ever use of zolpidem, compared with never use of zolpidem. The adjusted OR of HCC was 1.01 for subjects with increasing cumulative duration of zolpidem use for every 1 year (95% CI 0.99, 1.03), compared with never use of zolpidem.Conclusion: There is no significant association between HCC risk and zolpidem use. There is no duration-dependent effect of zolpidem use on HCC risk.http://journal.frontiersin.org/article/10.3389/fphar.2017.00767/fullhepatocellular carcinomazolpidemTaiwanNational Health Insurance Program |
| spellingShingle | Shih-Wei Lai Shih-Wei Lai Cheng-Li Lin Cheng-Li Lin Kuan-Fu Liao Kuan-Fu Liao Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan Frontiers in Pharmacology hepatocellular carcinoma zolpidem Taiwan National Health Insurance Program |
| title | Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan |
| title_full | Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan |
| title_fullStr | Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan |
| title_full_unstemmed | Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan |
| title_short | Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan |
| title_sort | zolpidem administration and risk of hepatocellular carcinoma a case control study in taiwan |
| topic | hepatocellular carcinoma zolpidem Taiwan National Health Insurance Program |
| url | http://journal.frontiersin.org/article/10.3389/fphar.2017.00767/full |
| work_keys_str_mv | AT shihweilai zolpidemadministrationandriskofhepatocellularcarcinomaacasecontrolstudyintaiwan AT shihweilai zolpidemadministrationandriskofhepatocellularcarcinomaacasecontrolstudyintaiwan AT chenglilin zolpidemadministrationandriskofhepatocellularcarcinomaacasecontrolstudyintaiwan AT chenglilin zolpidemadministrationandriskofhepatocellularcarcinomaacasecontrolstudyintaiwan AT kuanfuliao zolpidemadministrationandriskofhepatocellularcarcinomaacasecontrolstudyintaiwan AT kuanfuliao zolpidemadministrationandriskofhepatocellularcarcinomaacasecontrolstudyintaiwan |